Advertisement

Tumor Biology

, Volume 37, Issue 8, pp 11457–11467 | Cite as

MAP4K4 promotes epithelial-mesenchymal transition and metastasis in hepatocellular carcinoma

  • Xiao-Jun Feng
  • Qing Pan
  • Shou-Mei Wang
  • Yun-cui Pan
  • Qian Wang
  • Huan-Huan Zhang
  • Ming-Hua Zhu
  • Shu-Hui Zhang
Original Article

Abstract

Our previous study has reported that mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4) regulates the growth and survival of hepatocellular carcinoma (HCC) cells. This study was undertaken to explore the roles of MAP4K4 in the epithelial-mesenchymal transition (EMT) and metastasis in HCC. Effects of overexpression and knockdown of MAP4K4 on the migration, invasion, and EMT of HCC cells were examined. The in vivo role of MAP4K4 in lung metastasis of HCC was determined in nude mice. The relationship between MAP4K4 expression and EMT in human HCC specimens was determined by immunohistochemistry. MAP4K4 overexpression significantly enhanced the migration and invasion of MHCC-97L HCC cells, whereas MAP4K4 silencing hindered the migration and invasion of MHCC-97H HCC cells. MAP4K4-overexpressing cells undergo EMT, which was accompanied by downregulation of E-cadherin and upregulation of vimentin. In contrast, MAP4K4 silencing caused a reversion from a spindle morphology to cobblestone-like morphology and induction of E-cadherin and reduction of vimentin. Pretreatment with chemical inhibitors of JNK and NF-κB abolished MAP4K4-mediated migration, invasion, and regulation of EMT markers in MHCC-97L cells. Ectopic expression of MAP4K4 promoted and knockdown of MAP4K4 inhibited lung metastasis of HCC, which was associated with regulation of JNK and NF-κB signaling and EMT markers. High MAP4K4 immunoreactivity was inversely correlated with E-cadherin and was positively correlated with vimentin, phospho-JNK, and phospho-NF-κB in HCC specimens. Taken together, MAP4K4 promotes the EMT and invasiveness of HCC cells largely via activation of JNK and NF-κB signaling.

Keywords

Hepatocellular carcinoma MAP4K4 Epithelial-mesenchymal transition Invasion Metastasis 

Notes

Compliance with ethical standard

Funding

This work was supported in part by grants from National Nature Science Foundation of China (No. 81072020 and 81172311 to S.H. Zhang) and from “085” and “Integrated Traditional Chinese and Western Medicine” first-class discipline construction of science and technology innovation in Shanghai University of Traditional Chinese Medicine (No. 085ZY1220 to S.H. Zhang).

Conflict of interest

None

Supplementary material

13277_2016_5022_MOESM1_ESM.jpg (618 kb)
ESM 1 (JPG 618 kb)
13277_2016_5022_MOESM2_ESM.jpg (2.2 mb)
ESM 2 (JPG 2244 kb)
13277_2016_5022_MOESM3_ESM.jpg (411 kb)
ESM 3 (JPG 411 kb)
13277_2016_5022_MOESM4_ESM.doc (190 kb)
ESM 4 (DOC 190 kb)

References

  1. 1.
    Boyle P, Levin B. World cancer report 2008. Avenue, Geneva, Switzerland: WHO Press; 2009. p. 350.Google Scholar
  2. 2.
    Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist. 2010;15 Suppl 4:5–13.CrossRefPubMedGoogle Scholar
  3. 3.
    Tabrizian P, Roayaie S, Schwartz ME. Current management of hepatocellular carcinoma. World J Gastroenterol. 2014;20:10223–37.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139:871–90.CrossRefPubMedGoogle Scholar
  5. 5.
    Theys J, Jutten B, Habets R, Paesmans K, Groot AJ, Lambin P, et al. E-cadherin loss associated with EMT promotes radioresistance in human tumor cells. Radiother Oncol. 2011;99:392–7.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Smith BN, Bhowmick NA. Role of EMT in metastasis and therapy resistance. J Clin Med 2016; pii: E17Google Scholar
  7. 7.
    Dong Q, Zhu X, Dai C, Zhang X, Gao X, Wei J, et al. Osteopontin promotes epithelial-mesenchymal transition of hepatocellular carcinoma through regulating vimentin. Oncotarget. 2016. doi: 10.18632/oncotarget.7016.Google Scholar
  8. 8.
    Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, et al. EMT and dissemination precede pancreatic tumor formation. Cell. 2012;148:349–61.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Dai W, Wang F, He L, Lin C, Wu S, Chen P, et al. Genistein inhibits hepatocellular carcinoma cell migration by reversing the epithelial-mesenchymal transition: partial mediation by the transcription factor nfat1. Mol Carcinog. 2015;54:301–11.CrossRefPubMedGoogle Scholar
  10. 10.
    Davis FM, Stewart TA, Thompson EW, Monteith GR. Targeting EMT in cancer: opportunities for pharmacological intervention. Trends Pharmacol Sci. 2014;35:479–88.CrossRefPubMedGoogle Scholar
  11. 11.
    Vitorino P, Yeung S, Crow A, Bakke J, Smyczek T, West K, et al. Map4k4 regulates integrin-ferm binding to control endothelial cell motility. Nature. 2015;519:425–30.CrossRefPubMedGoogle Scholar
  12. 12.
    Yue J, Xie M, Gou X, Lee P, Schneider MD, Wu X. Microtubules regulate focal adhesion dynamics through map4k4. Dev Cell. 2014;31:572–85.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Collins CS, Hong J, Sapinoso L, Zhou Y, Liu Z, Micklash K, et al. A small interfering RNA screen for modulators of tumor cell motility identifies map4k4 as a promigratory kinase. Proc Natl Acad Sci U S A. 2006;103:3775–80.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Liu AW, Cai J, Zhao XL, Jiang TH, He TF, Fu HQ, et al. Shrna-targeted map4k4 inhibits hepatocellular carcinoma growth. Clin Cancer Res. 2011;17:710–20.CrossRefPubMedGoogle Scholar
  15. 15.
    Liang JJ, Wang H, Rashid A, Tan TH, Hwang RF, Hamilton SR, et al. Expression of map4k4 is associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma. Clin Cancer Res. 2008;14:7043–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Zhao G, Wang B, Liu Y, Zhang JG, Deng SC, Qin Q, et al. Mirna-141, downregulated in pancreatic cancer, inhibits cell proliferation and invasion by directly targeting map4k4. Mol Cancer Ther. 2013;12:2569–80.CrossRefPubMedGoogle Scholar
  17. 17.
    Toiyama Y, Yasuda H, Saigusa S, Tanaka K, Inoue Y, Goel A, et al. Increased expression of slug and vimentin as novel predictive biomarkers for lymph node metastasis and poor prognosis in colorectal cancer. Carcinogenesis. 2013;34:2548–57.CrossRefPubMedGoogle Scholar
  18. 18.
    Schneider MR, Hiltwein F, Grill J, Blum H, Krebs S, Klanner A, et al. Evidence for a role of E-cadherin in suppressing liver carcinogenesis in mice and men. Carcinogenesis. 2014;35:1855–62.CrossRefPubMedGoogle Scholar
  19. 19.
    Qiu MH, Qian YM, Zhao XL, Wang SM, Feng XJ, Chen XF, et al. Expression and prognostic significance of map4k4 in lung adenocarcinoma. Pathol Res Pract. 2012;208:541–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Zohn IE, Li Y, Skolnik EY, Anderson KV, Han J, Niswander L. P38 and a p38-interacting protein are critical for downregulation of E-cadherin during mouse gastrulation. Cell. 2006;125:957–69.CrossRefPubMedGoogle Scholar
  21. 21.
    Song FN, Duan M, Liu LZ, Wang ZC, Shi JY, Yang LX, et al. Rankl promotes migration and invasion of hepatocellular carcinoma cells via NF-kappab-mediated epithelial-mesenchymal transition. PLoS One. 2014;9, e108507.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Song R, Song H, Liang Y, Yin D, Zhang H, Zheng T, et al. Reciprocal activation between ATPase inhibitory factor 1 and NF-kappab drives hepatocellular carcinoma angiogenesis and metastasis. Hepatology. 2014;60:1659–73.CrossRefPubMedGoogle Scholar
  23. 23.
    Ching YP, Leong VY, Lee MF, Xu HT, Jin DY, Ng IO. P21-activated protein kinase is overexpressed in hepatocellular carcinoma and enhances cancer metastasis involving c-Jun NH2-terminal kinase activation and paxillin phosphorylation. Cancer Res. 2007;67:3601–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Tsai JP, Hsiao PC, Yang SF, Hsieh SC, Bau DT, Ling CL, et al. Licochalcone a suppresses migration and invasion of human hepatocellular carcinoma cells through downregulation of mkk4/JNK via NF-kappab mediated urokinase plasminogen activator expression. PLoS One. 2014;9, e86537.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Zhu XL, Wang YL, Chen JP, Duan LL, Cong PF, Qu YC, et al. Alternol inhibits migration and invasion of human hepatocellular carcinoma cells by targeting epithelial-to-mesenchymal transition. Tumour Biol. 2014;35:1627–35.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Xiao-Jun Feng
    • 1
    • 4
  • Qing Pan
    • 2
  • Shou-Mei Wang
    • 1
  • Yun-cui Pan
    • 1
  • Qian Wang
    • 1
  • Huan-Huan Zhang
    • 1
  • Ming-Hua Zhu
    • 3
  • Shu-Hui Zhang
    • 1
  1. 1.Department of Pathology, Yueyang Hospital of Integrated Traditional Chinese and Western MedicineShanghai University of Traditional Chinese MedicineShanghaiChina
  2. 2.Department of PathologyTongde Hospital of Zhejiang ProvinceHangzhouChina
  3. 3.Department of Pathology, Changhai Hospital and Institute of Liver DiseasesSecond Military Medical UniversityShanghaiChina
  4. 4.Changxing Chinese medicine hospitalHuzhouChina

Personalised recommendations